I'll verify the company's profile before writing.
Company overview. Boehringer Ingelheim Pharmaceuticals, Inc. is the U.S. prescription-pharmaceutical operating subsidiary of the Boehringer Ingelheim group, headquartered at 900 Ridgebury Road, Ridgefield, Connecticut; it is a Delaware corporation qualified in the U.S. since 1971. Per its Rule 7.1 disclosure statement in the case below, its corporate parent is C. H. Boehringer Sohn AG & Co. KG, the family-owned holding company of the group (group HQ: Ingelheim am Rhein, Germany; founded 1885). The group is privately held, not publicly traded, and reported 2024 net sales of €26.8 billion with roughly 54,500 employees worldwide and ~€6.2 billion (~23% of sales) spent on R&D (company "2024 Highlights"; boehringer-ingelheim.com).
Products / operations. It is a research-based pharmaceutical manufacturer, not an NPE. Group operations span two business units: Human Pharma and Animal Health, the latter among the world's largest veterinary vaccine and therapeutic businesses. Human Pharma focuses on cardiovascular/metabolic, oncology, respiratory, immunology, mental health and retinal health, with marketed brands including Jardiance (empagliflozin), Trajenta/Jentadueto (linagliptin), Spiriva, Ofev and Pradaxa (company materials).
Patent-litigation posture. Our database shows one tracked matter, with this entity as plaintiff and zero as defendant — consistent with an operating company enforcing brand patents, not a patent assertion entity. Specifically, it is an active Hatch-Waxman/ANDA plaintiff in the District of Delaware, a common venue for pharmaceutical ANDA actions. Its litigation arises from FDA Paragraph IV certifications by generic filers rather than from an acquired assertion portfolio. The single-case count reflects this database's coverage, not Boehringer's overall litigation volume.
Notable case. Boehringer Ingelheim Pharmaceuticals Inc. et al. v. Granules India Limited (D. Del. 1:25-cv-00663, filed May 29, 2025) asserted four patents (U.S. 9,949,998; 10,258,637; 11,090,323; 11,833,166) against Granules' ANDA No. 220408 for 10 mg and 25 mg generic empagliflozin tablets, a generic version of Jardiance. The parties resolved the case by consent judgment entered September 2, 2025, which enjoined Granules' ANDA product until patent expiry and dismissed co-plaintiff Boehringer Ingelheim Corporation with prejudice (court docket/consent judgment).